Compare Fresenius Kabi Onco. with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs GSK PHARMA - Comparison Results

FRESENIUS KABI ONCO.     Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. GSK PHARMA FRESENIUS KABI ONCO./
GSK PHARMA
 
P/E (TTM) x 22.1 52.1 42.5% View Chart
P/BV x 3.1 11.0 28.4% View Chart
Dividend Yield % 0.0 1.4 -  

Financials

 FRESENIUS KABI ONCO.   GSK PHARMA
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
GSK PHARMA
Mar-19
FRESENIUS KABI ONCO./
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs1763,595 4.9%   
Low Rs791,253 6.3%   
Sales per share (Unadj.) Rs37.7184.7 20.4%  
Earnings per share (Unadj.) Rs5.126.3 19.4%  
Cash flow per share (Unadj.) Rs6.729.2 23.1%  
Dividends per share (Unadj.) Rs020.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs42.5126.3 33.7%  
Shares outstanding (eoy) m158.23169.40 93.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.413.1 25.7%   
Avg P/E ratio x25.092.2 27.1%  
P/CF ratio (eoy) x18.983.1 22.8%  
Price / Book Value ratio x3.019.2 15.6%  
Dividend payout %076.1 0.0%   
Avg Mkt Cap Rs m20,135410,626 4.9%   
No. of employees `0001.25.0 23.2%   
Total wages/salary Rs m7035,372 13.1%   
Avg. sales/employee Rs Th5,176.26,306.7 82.1%   
Avg. wages/employee Rs Th610.41,083.1 56.4%   
Avg. net profit/employee Rs Th699.6898.0 77.9%   
INCOME DATA
Net Sales Rs m5,96331,281 19.1%  
Other income Rs m181,023 1.8%   
Total revenues Rs m5,98132,304 18.5%   
Gross profit Rs m1,4306,009 23.8%  
Depreciation Rs m258486 53.1%   
Interest Rs m-266 -433.3%   
Profit before tax Rs m1,2166,540 18.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-68287 -23.7%   
Tax Rs m3422,373 14.4%   
Profit after tax Rs m8064,454 18.1%  
Gross profit margin %24.019.2 124.9%  
Effective tax rate %28.136.3 77.5%   
Net profit margin %13.514.2 94.9%  
BALANCE SHEET DATA
Current assets Rs m5,10220,061 25.4%   
Current liabilities Rs m2,38514,543 16.4%   
Net working cap to sales %45.617.6 258.2%  
Current ratio x2.11.4 155.0%  
Inventory Days Days15057 264.3%  
Debtors Days Days11314 805.7%  
Net fixed assets Rs m5,14814,343 35.9%   
Share capital Rs m1581,694 9.3%   
"Free" reserves Rs m6,55619,704 33.3%   
Net worth Rs m6,73221,398 31.5%   
Long term debt Rs m9522 47,610.0%   
Total assets Rs m10,38839,113 26.6%  
Interest coverage x-45.81,091.0 -4.2%   
Debt to equity ratio x0.10 151,337.3%  
Sales to assets ratio x0.60.8 71.8%   
Return on assets %7.511.4 65.8%  
Return on equity %12.020.8 57.5%  
Return on capital %14.631.9 45.7%  
Exports to sales %74.50-   
Imports to sales %24.80-   
Exports (fob) Rs m4,441NA-   
Imports (cif) Rs m1,477NA-   
Fx inflow Rs m5,298534 992.1%   
Fx outflow Rs m1,7727,091 25.0%   
Net fx Rs m3,525-6,557 -53.8%   
CASH FLOW
From Operations Rs m1,2743,994 31.9%  
From Investments Rs m-1,204-1,433 84.0%  
From Financial Activity Rs m-196-3,584 5.5%  
Net Cashflow Rs m-126-1,023 12.3%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 81.0 50.7 159.8%  
Indian inst/Mut Fund % 0.3 10.2 2.9%  
FIIs % 9.6 23.8 40.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 15.4 59.1%  
Shareholders   42,599 102,036 41.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   ABBOTT INDIA  JUBILANT LIFE SCIENCES  BIOCON   IPCA LABS  NATCO PHARMA  

Compare FRESENIUS KABI ONCO. With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)

Jul 24, 2019 | Updated on Jul 24, 2019

For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

GSK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 16.6% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 16.6% YoY). Sales on the other hand came in at Rs 8 bn (up 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 26.0% (Quarterly Result Update)

Feb 5, 2019 | Updated on Feb 5, 2019

For the quarter ended December 2018, GSK PHARMA has posted a net profit of Rs 1 bn (up 26.0% YoY). Sales on the other hand came in at Rs 8 bn (up 17.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 22.7% (Quarterly Result Update)

Oct 23, 2018 | Updated on Oct 23, 2018

For the quarter ended September 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 22.7% YoY). Sales on the other hand came in at Rs 8 bn (down 2.4% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

My 7 Stocks to Buy Are Companies Which Will Be a Big Part of New India(The 5 Minute Wrapup)

Sep 19, 2019

The India we knew is changing. Here's how you can benefit from this change.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. - AJANTA PHARMA COMPARISON

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS